Background
Phase 3, randomized, double-blind, placebo-controlled trial. 178 patients with RBC transfusion-dependent lower-risk MDS (IPSS Low or Int-1), ESA-relapsed, ESA-refractory, or ESA-ineligible. Randomized 2:1 (imetelstat 118, placebo 60). Stratified by prior transfusion burden and IPSS risk group. 118 sites in 17 countries.
Interventions and follow up
Arm A: Imetelstat 7.5 mg/kg IV infusion over 2 hours every 4 weeks (n=118)
Arm B: Placebo IV every 4 weeks (n=60)
Primary endpoint: RBC transfusion independence ≥8 consecutive weeks (ITT)
mFollow up: Median 19.5 months (imetelstat), 17.5 months (placebo)
Arm B: Placebo IV every 4 weeks (n=60)
Primary endpoint: RBC transfusion independence ≥8 consecutive weeks (ITT)
mFollow up: Median 19.5 months (imetelstat), 17.5 months (placebo)
Results
RBC-TI ≥8 weeks: 40% (47/118) vs 15% (9/60), rate difference 25% (95% CI 9.9–36.9), P=.0008
Median duration of RBC-TI: Approximately 1 year (durable)
Median duration of RBC-TI: Approximately 1 year (durable)
Adverse events
Overall: Grade 3–4 treatment-emergent AEs 91% (imetelstat) vs 47% (placebo)
Hematologic: Grade 3–4 neutropenia 68% vs 3%; grade 3–4 thrombocytopenia 62% vs 8% — dominant safety concern, managed with dose modification
Other: No treatment-related deaths reported
Hematologic: Grade 3–4 neutropenia 68% vs 3%; grade 3–4 thrombocytopenia 62% vs 8% — dominant safety concern, managed with dose modification
Other: No treatment-related deaths reported
Conclusions
Imetelstat significantly increased rates of durable transfusion independence versus placebo in heavily pre-treated, ESA-refractory/ineligible LR-MDS, with responses lasting approximately one year. The telomerase-inhibitory mechanism offers a disease-modifying approach distinct from ESAs and luspatercept.
Key Limitations
High rates of grade 3–4 cytopenias (neutropenia 68%, thrombocytopenia 62%) substantially exceed the placebo arm and require close monitoring and dose adjustment. The 2:1 randomization and relatively small placebo group limit precision of comparative estimates. OS data are immature; no survival benefit yet demonstrated. The trial includes only ESA-refractory patients — not directly comparable to COMMANDS or MEDALIST. Patients with higher-risk MDS were excluded.
Clinical Context
IMerge supported FDA approval of imetelstat (Rytelo) for transfusion-dependent LR-MDS in June 2024, the first telomerase inhibitor approved in oncology. It is positioned as a third-line option after failure of both ESA and luspatercept. Its disease-modifying potential (clonal suppression via telomerase inhibition) distinguishes it mechanistically, though OS benefit remains unproven. The hematologic toxicity profile requires careful patient selection and monitoring infrastructure.